11.00
Iovance Biotherapeutics Inc stock is traded at $11.00, with a volume of 12.59M.
It is up +1.85% in the last 24 hours and up +30.33% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$10.80
Open:
$10.9
24h Volume:
12.59M
Relative Volume:
0.76
Market Cap:
$4.98B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-11.58
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
+7.32%
1M Performance:
+30.33%
6M Performance:
+193.33%
1Y Performance:
+444.55%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics Inc
|
11.00 | 4.98B | 285.55M | -353.86M | -305.02M | -0.9501 |
|
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Iovance Biotherapeutics, Inc. (IOVA) Options Chain - Yahoo! Finance Canada
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Iovance Biotherapeutics stock hits 52-week high at 10.98 USD - Investing.com
Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs - Moomoo
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Why Iovance Biotherapeutics Stock Was on Fire Today - The Globe and Mail
IOVA Reinstated by Goldman Sachs -- Buy Rating with Price Target of $15.00 - GuruFocus
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics (IOVA) w - GuruFocus
IOVA Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics, Inc. (IOVA) stock price, news, quote and history - Yahoo Finance UK
Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics stock extends rally after strong earnings and cancer therapy momentum - AD HOC NEWS
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Iovance Biotherapeutics Stock: 6 Straight Green Days, Up 26% - Trefis
Why Did Iovance Biotherapeutics (IOVA) Move Today? - finance.yahoo.com
Iovance Biotherapeutics (IOVA) Is Up 19.2% After Record Q2 Amtagvi Revenue And TIL Pipeline Expansion - finance.yahoo.com
Iovance Biotherapeutics (IOVA) Stock Fair Value Edges Higher On Amtagvi Margin Progress - Yahoo Finance
Is Iovance Biotherapeutics (IOVA) Trading At A Premium To Sales? - finance.yahoo.com
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Moomoo
Iovance Biotherapeutics (IOVA) Stock Forum and Discussion - Moomoo
Iovance Biotherapeutics (IOVA) Puts Buyer Nets 64% Gain as Marke - GuruFocus
Iovance Biotherapeutics (IOVA) Stock Analysis: Unpacking the 65.7% Revenue Growth Potential - DirectorsTalk Interviews
$Iovance Biotherapeutics (IOVA.US)$ - Moomoo
$Iovance Biotherapeutics (IOVA.US)$ Talking a profit here and waiting for it to come down closer to 9 ema - Moomoo
IOVA Maintained by Barclays -- Price Target Raised to $15.00 - GuruFocus
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15 - Moomoo
IOVA Stock Has Gained More Than 21% In Four Sessions, And Barclays Sees Another 52% Upside PotentialHere’s Why - finance.yahoo.com
Iovance Biotherapeutics stock hits 52-week high at 9.36 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics stock hits 52-week high at 9.36 USD - Investing.com
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - Stocktwits
Why Did IOVA Stock Gain Pre-Market Today? - Stocktwits
Iovance Biotherapeutics' Chief Regulatory Officer Reports RSU Vesting and Tax Withholding Transactions - Kalkine Media
Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com Australia
Iovance Biotherapeutics (IOVA) Slips 3.10% to $8.43 as Support at $8.01 Comes Into FocusAlgorithmic Stock Picks - careplusvn.com
Iovance Biotherapeutics stock trends on sector momentum, Q2 beat - scanx.trade
Why Is IOVA Stock Falling Today? - Stocktwits
NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing - Stock Traders Daily
Iovance Biotherapeutics Stock Price Forecast. Should You Buy IOVA? - StockInvest.us
Iovance Biotherapeutics, Inc. (IOVA) Latest Press Releases & Corporate News - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance
Iovance Biotherapeutics to Present at Upcoming Conferences - The Manila Times
Iovance Biotherapeutics (IOVA) Stands Out with Strong Quant Rati - GuruFocus
Iovance Biotherapeutics (IOVA) Wins FDA Trial Clearance, Is The Stock Still 54% Undervalued? - sahmcapital.com
Iovance Biotherapeutics Inc. (IOVA) Peer Comparison – Compare with Others - Value Research
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):